Aethlon medical announces investigation of the hemopurifier® for use in organ transplantation

Research to confirm the hemopurifier's ability to remove harmful viruses and exosomes from harvested organs san diego , june 21, 2023 /prnewswire/ -- aethlon medical, inc. (nasdaq: aemd), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is investigating the use of its hemopurifier® in the organ transplant market, in addition to its ongoing studies in cancer and covid-19. "our objective is to confirm that the hemopurifier, in our translational studies, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes from harvested organs," stated charles j.
AEMD Ratings Summary
AEMD Quant Ranking